CA1268123A - Dietary products and uses comprising methylsulfonylmethane - Google Patents

Dietary products and uses comprising methylsulfonylmethane

Info

Publication number
CA1268123A
CA1268123A CA000507074A CA507074A CA1268123A CA 1268123 A CA1268123 A CA 1268123A CA 000507074 A CA000507074 A CA 000507074A CA 507074 A CA507074 A CA 507074A CA 1268123 A CA1268123 A CA 1268123A
Authority
CA
Canada
Prior art keywords
methylsulfonylmethane
foodstuff
animal
animals
ppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000507074A
Other languages
French (fr)
Other versions
CA1268123C (en
Inventor
Robert J. Herschler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24924965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1268123(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to CA507074A priority Critical patent/CA1268123C/en
Application granted granted Critical
Publication of CA1268123A publication Critical patent/CA1268123A/en
Publication of CA1268123C publication Critical patent/CA1268123C/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/152Milk preparations; Milk powder or milk powder preparations containing additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/105Aliphatic or alicyclic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/20Synthetic spices, flavouring agents or condiments
    • A23L27/202Aliphatic compounds
    • A23L27/2022Aliphatic compounds containing sulfur
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03Organic compounds
    • A23L29/055Organic compounds containing sulfur as heteroatom
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A24TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24BMANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18Treatment of tobacco products or tobacco substitutes
    • A24B15/28Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/32Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by acyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/004Aftersun preparations

Abstract

"DIETARY PRODUCTS AND USES
COMPRISING METHYLSULFONYLMETHANE"

ABSTRACT OF THE DISCLOSURE
Methylsulfonylmethane is effective in maintaining good health and in improving poor health of animals, including human beings and is an assimilable source of dietetic sulfur.

Description

3~

BACKGROUND OF THE INVENTION

This invention relates to dietary compositions com-prising and methods of using methylsulfonylmethane (MSM).
In my prior U.S. Patent 4,Z96,130, I disclose com-positions containing methylsulfonylmethane to soften, smooth, lubricate and preserve the pliancy of human tis-sues and for reducing the brittleness of finger and toe nails. I disclose therein that methylsulfonylmethane is substantially inert to the chemistry of the body and, because of its extremely low toxicity and inertness to the diverse chemical reactions involved in the life processes, it can be used as a diluer,t for blood. The ingestion of oral compositions is disclosed therein to preserve the pliancy of intestinal and other tissue. U.S. 4,477,469 relates to methylsulfonylmethane and carbamide composi-tions. U.S. 4,514,421 relates to methods of ameliorating ,t~
q~

12~81;~;~

symptoms of stress of allergy with methylsulfonylmethane.
U.S. 4,296,104 discloses DMSO compositions which optionally can contain a protein modifying agent, such as methylsulfonylmethane. I~.S. 4,112,946 discloses the use of an aqueous solvent system comprising methylsulfonylmethane in a process for the introduction of a health modifying agent into water-living animals as an osmotic factor. U .S.
4,568,547 relates to the use of methylsulfonylmethane as the diluent or carrier for storage unstable pharmaceutically active agents. U.S. 4,559,329 relates to oral pharmaceutical compositions comprising a gastrointestinal upset-promoting pharmaceutical and an ameliorating amount of methylsulfonylmethane.
J. J. Kocsis et al, Annals N.Y. Acad. Sci. 243, 104-109 (1975), cite literature which report that methyl-sulfonylmethane, as known metabolite of dimethylsulfoxide, persists for as long as three weeks after percutaneous application in man and one week after i.v. administration.
The authors report that methylsulfonylmethane, like DMSO, enhances urinary taurine secretion produced by aromatic hydrocarbons in man, antagonizes the lethal effects of anticholinesterases such as paraoxon, tetraethyl pyro-phosphate and octamethyl pyrophosphoramide; lowers the body temperature of rates exposed to 5C temperature; and reduces motor activity (when administered i. p.). Kulshestha et al, C .A . 83; 2291On ( 1975 ), report that methylsulfonylmethane occurs naturally in a variety of fruits, vegetables and vegetable products, grains in at least trace amounts ( 3.3 ppm). T. W. Pearson et al, C.A.
95:113654w (1981). It is present in small amounts in normal urine. Williams et al., Archs. Biochem. Biophys.
1966, 113, 251-2. The following Chemical Abstracts refer to the biological aspects of methylsulfonylmethane as a DNSO metabolite, in cattle, 83:183a; Escherichia coli inhibition by, 83:72577e; nervous system depression by, .

~` ~2681~3 84:173608a; Salmonella typhimurium inhibition by, 82:71;
of urine, 75:86025v; heart response to, 74:2429y; lung constrictivity activity of, 62:9634f; in tissue culture protection against X-rays, 58:9391e; toxicity of, ETOH
and, 64:7229h; in urine after administration of, 65:17537g; in urine of humans, 64:10170g; and in urine as methylsulfonylmethane metabolite, 64:7213a; 65:17535b.
Siegel, (1985, Private Communication) has evaluated methylsulfonylmethane in mice with a genetic predisposi-tion to a form of canceE and rheumatoid aEthEitis. The ,~ sulfone was administered orally. There was a significant delay in the development of lymphomas as well as decreased tumor incidence, compared with control. In addition and only grossly examined, treated animals demonstrated a marked reduction in joint involvement. An in~reased titerof primary IgM and secondary IgG was measured.
In a separate pilot study, female rats given an abdomina} application o DMBA while EeCeiV~ng methylsul-onylmethane in theiE dEinking! water didi not develop tumors, while mammaEy tumoEs WeEe seen in control animals.
Waltering, ~. an~ Jaimes, k. tl985, Private Communication).
Metcalf, ~., L. Eguine ~et. Sci. 3~5~,:148-174 ~1~&3~ describes the benefits obseEve~ when methylsulfo-n~tmethane was adde~ to the diet of- animails. One dis-2S oEdeE, epiphysitis, involving calcium~phosphoFous imbal-ance in the horse was rapidly corrected with oral methyl-sulfonylmethane.
I have found that notwithstanding its extreme lack of toxicity and inertness of the diverse chemical reac-tions involved in the life processes, surprisingly methyl-sulfonylmethane nevertheless is metabolized sufficiently to supply the nutritional sulfur requirements of animals, including humans and other vertebrates, whose diet is deficient in assimilable sulfur. The incidence of such assimilable sulfur-deficient diets is very high because of ~2~i8123, ..
the high percentage of processed foodstuffs therein in advanced cultures.
I have also found that in addition to the pharma-cologically beneficial effects methylsulfonylmethane has in humans and other animals which are specifically dis-closed in my parent applications, it is useful in the treatment of a surprising variety of other diseases and adverse physiological conditions, as disclosed in detail hereinafter.
Since the early part of 1983, methylsulfonylmethane has been sold in tablet form (250 mg) as a dietary sup-plement.
Obiects o the Invention It is an object of this invention to pEovide a method employing methylsulfonylmethane for coEre~ting metabolizable sulfur-deficient diets.
It is anotheE object to provide a method foE
treating diverse and adverse physiological conditions in humans and otheE animals with methylsulfonylmethane.
It is a uEthe~ object to provide novel methylsul-fonylmethane-containing compositions.
Upon further study of the specification and appended claims, further ob~ects and advantages o this invention will become apparent to those skilled in the art.
Summary of the Invention In one method-of-use aspect, this invention Eelates to a method o pEocessing a foodstuf which involves the step of reducing the moisture content thereof by heating or drying sufficiently to reduce any naturally occurring methylsulfonylmethane present therein to a level of less than about 0.01 ppm, the improvement which comprises admixing with the foodstuff after said step an amount of methylsulfonylmethane effective to raise the concentration thereof in the foodstuff to at least about 0.01 ppm.

i81;~3 In another method-of-use aspect, this invention relates to a method of improving the overall state of health and resistance to disease of an animal maintained on a diet which supplies naturally occurring methylsulfo-nylmethane in amounts insufficient to maintain body levelsthereof in the animal of at least 1 ppm, which comprises adding to the diet of the animal an amount of methylsul-fonylmethane effective to maintain these body levels at at least 1 ppm.
In another method-of-use aspect, this invention relates to a method o ameliorating the pain and discom-~;~
~ort associated with arthritis in an animal which com-prises administering to an animal manifesting overt symp-toms of the dlsease an amount o methylsulfonylmethane effective to ameliorate the pain.
In another method-of-use aspect, this invention relates to a method of alleviating intractible pain, which ; compEises administering intravenously to a patient suf-i~ fering Çrom a disease produ¢ing such pain an amount of methylsulfonylmethane effective to alleviate the pain.
In another method-of-use aspect, this invention relates to a method of treating a patient systemically infected with a parasite against which methylsulfonyl-methane e~hibits in vitro toxicity, which comprises administeEing systemically to the patient an amount o~
methylsulfonylmethane effective to inhibit the growth of the parasite in the patient.
In another method-of-use aspect, this invention relates to a method of inhibiting nocturnal and arthritic activity-induced muscle cramps in a person having a pro-pensity for such muscle cramps, which comprises orally ingesting an amount of methylsulfonylmethane effective to inhibit the muscle cramps.
In other method-of-use aspect, this invention relates to the treatment of other adverse physiological 12681~

conditions with methylsulfonylmethane.
In a process aspect this invention relates to a method of processing a foodstuff which involves the step of reducing the moisture content thereof by heating or drying sufficiently to reduce any naturally occurring methyl-sulfonylmethane present therein to a level of less than about 0.01 ppm, the improvement which comprises admixing with the foodstuff after said step an amount of methylsulfonylmethane effective to raise the concentration thereof in the foodstuff l to at least about 0.01 ppm.
In a composition aspect, this invention relates to a processed foodstuff containing less than about 15 ppm of naturally occurring methylsulfonylmethane, in admixture with from about 15 x 10-4% to 3.0% of methylsulfonylmethane.
Other aspects of this invention will be apparent to those skilled in the art to which this invention pertains.
Detailed Discussion -Notwithstanding the fact that methylsulfonylmethane is omnipotent in body fluids and is so non-toxic that it can be used as a diluent for blood without upsetting the blood chemistry, as disclosed and claimed in U.S. 4,514,421 and U.S. 4,559,329, at daily dosages of at least about 100 mg, methylsulfonylmethane is an ameliorating agent for a variety of pathological conditions when administered systematically and preferably orally to persons displaying symptoms of physiological response to stress, e.g., gastrointestinal distress, inflammation of the mucous membranes and allergic reactions.
Methylsulfonylmethane and many precursor compounds which are readily converted to methylsulfonylmethane in the body, are normal ingredients found in most natural, i.e., unprocessed foods consumed by man and other animals.
Methylsulfonylmethane and its precursors have been avail-able as nutritional and possibly essential factors in the ~i812;~

vertebrate diet long before terrestrial life occurred.
Methylsulfonylmethane has multiple functions in the body.
At low levels of ingestion, it functions as a normal die-tary ingredient, viz., as a food or food ingredient; at higher levels it functions as a pharmaceutically active agent.
Sulfur also plays important roles in the body, including the forming of "tie-bars" or disulfide bonds hoIding molecular strands of connective tissue together.
It plays many other essential roles, such as determining the contour of diverse biomolecules, and is essential to the activity of many enzymes that protect and~ sustain life processes. To perform these roles, constant intake o assimilable sulfur is needed by the body. Heretoore, it was believed that ingested protein supplied su~fi~ient metabolic sulfur for balanced nutritional needs. However, it now appears that this is not the case and that methyl-sulfonylmethane ingestion is Eequired in order to maintain nutritionally adequate levels o assimilable sulur in the body. While it was known for several decades that methyl-sulonylmethane was a normal constituent o the body, ,;, there was no recognition o the impoEtance of its EO~e in animal nutEition and good health. W~ith~ today'~ modeE~
diet of cooked and otherwise~ pEocessed~ and dilutedl foods, most i not all diets of civilized man and domesticated lower animals are deficient in this criticaIly important ingredient.
Methylsulfonylmethane is a key nutritional ingre-dient, available and assimilated by all plant and animal life from their beginnings on earth. It is essential to a healthful diet and is a nutritional essence found in almost every fresh food of any origin now consumed by animal life. However, it is volatile and therefore read-ily becomes lost when fresh food is processed and/or stored.

;8~3 It is known that many foodstuffs are altered by conventional processing. For example, proteins are denatured or altered so that water soluble proteins become insoluble and insoluble protein becomes soluble, for example, the insolubilization of egg white by cooking and the conversion of collagen to soluble gelatin. Fats are altered when processed or stored and starches can be rendered either more OE less digestible. The average diet thus is deficient in methylsulfonylmethane because it is readily lost during conventional food processing, such as cooking, drying or dehydrating, dilution with synthetic fillers and otheE poor~y nutr-itiona~ addi~ives, eoo~}ng, radiation or pasteuEizing, and long-t~Em st~age. Thus, methylsulfonylmethane is SimilaE t~ vitamins and minerals which, as a general EU'l~ aEe als~ paEtially OE totally lost during noEmal processing.
Generally spea~ing, ~Eoeessing any food, as by heating or drying, essentially eliminates the biologically 'i' important, sulfur-Eieh ~about 1~3 by wt. of sulfur~
methylsulfonylmethane. SulfuE, a requi~ed ma~ronutEient, must be constantly replaeed in the matuEe animal and sup-plied or growth and good; healh in the yo~ng animal. An aspect of this invention iis the diSe~VeEy that methylsul-fonylmethane is a preeEEe~ dietaEy SouEee of sulfur.
25 Although methionine, a sulur-eontaining aminoaei~, may serve as a partia~ bac~-up souEe~ duEin~ blometabolism where the diet is methylsulonylmethane defieient, methi-onine demonstrates undesirable toxicity parameteres.
Studies to date indicate that it is desirable that 30 animals ingest about 0.5 - 1.0 milligram/kg body weight/
day of methylsulfonylmethane to maintain optimum good health. However, any lower level will serve some benefit.
Higher levels are either stored in the body as a sulfur reserve, provide a sufficient concentration to optimize 35 synthesis of the multitude o~ required sulfur containing ~L2~ 3 g biomolecules, or sim~y are excreted as by the renal ` pathway or through ~h skin. The intact molecule has been shown to beneficially effect tissue, as for example improving the pliability and softness of the skin.
It is also important to recognize that alternate food sources of utilizable sulfur in the diet are most costly and the most difficult foods to generally abtlin world-wide, for example fresh meat and fish. While fresh, unp~ocessed foods of plant and animal origin are the richest natural sources of methylsulfonylmethane, at best these are generally plentiful only seasonally. For geo-graphic, political, religious, cultural and economic reasons, m~n and lower animals heretoore are believed to have suffered an unrecognized dietary deficiency prevent-lS ing optimum health. This invention resolves this problem.
An individual consuming only unpasteurized milk,aW fish ana meats~ and uncooked, fresh vegetables and other plant-~eEive~ ood`s probably would deEive sufficient i~ naturally oeaurring methylsulfonylmethane and therefore not re~uiEe sul~ur supplements to the diet. Obviously this is impossible to achieve with customaEy meal prepa-ration, ood handling and storage. For example, milk, a food relatively rich in naturally occurEinq methylsulfo-nylmethane, loses a substantial poEtion o this compound as well as precursors, when subject to pasteurization to protect the product from microbial decomposition. Milk that has been spray dried, ordinarily is totally devoid of methylsulfonylmethane.
Domestic animals are dependent on man for their nutritional requirements. Because the majority of the food sources of domestic animals is now processed food, their diets are similarly subject to loss of valuable nutrients, including methylsulfonylmethane, during pro-cessing. Man cooks most foods and thus drives off most, if not all naturally occurring methylsulfonylmethane 12~i81'~,3 together with the precursors, and, accordingly, suffers a greater methylsulfonylmethane deficiency than any other animal.
As a basic supplier of metabolizable sulfur, methylsulfonylmethane is a foodstuff as well as being a natural ingredient of various foodstuffs. There are few, if any, natural and synthetic agents ingested by man and other animals as part o their diets that would not be improved nutritionally by methylsulfonylmethane being added thereto. Man and lower animals require about 1 mg/kg body weight of methylsulfonylmethane per day to replace the naturally occur}ing methylsulfonylmethane now lost in food processing.
Preferably, the methylsulfonylmethane is added to processed foods after pEoceSSing has been completed and to heated foods immediately before serving. Although methylsulfonylmethane taken alane or as solid or liquid orms taken in the manner of mineEals and vitamins would provide maximum benefits in maintaining good health, this procedure is not a~ways possible. TheEefore ane must consider a wide VaEiety of eompositio~s which when ingested will supply the eEitieal minimum o~ about 1 mg/kg body weight per day.
As well as pEoeessed foodstuffs, methylsulfonyl-methane can be ineoEpo}ated into salt, beveEages, spices,conventional vitamin and mineral products and other orally ingested products, such as confectiona}y products and chewing gum.
In numerous testings, methylsulfonylmethane has been found to enhance the flavor and improves the taste of many ingested products including foods, beverages, condi-ments and pleasure items such as chewing gum, breath sweeteners, lozenges and similar compositions.
Methylsulfonylmethane may also be included in certain non-food products, as for example, tobacco pro-12~;8~3 ducts. This can be accomplished by adding methylsulfonyl-methane dissolved in a tobacco humectant, such as a poly-hydric alcohol. A burning cigarette would provide sublimed methylsulfonylmethane along with the smoke.
Adding methylsulfonylmethane to the smo~e enhances its flavor and taste.
This invention is based in part on the discovery that inorganic hydrogen sulfide and sulfate salts are not the primary sources of sulfur required to balance the natural sulfur cycle. It has been theorized that simple organic molecules such as the methyl-S-methane series (S =
sulfenyl, sulfinyl or sulfonyl), available before or at the time the first simple life appeared on earth, are pEimary sources of the sulfur atom for sulfur containing biomolecules. Consistent with this proposal is the fact that methylsulfonylmethane is found natuEally in most foods of plant and animal OEigin as well as all the water (as marine derived rain) alling on earth.
SulCur is a EequiEed nutrient tfood) for biological normalcy of plants as well as animals and methylsulfonyl-methane plays a majoE Eole as the sulur-Eich food natu-,~ rally available to man and lower vertebEates. The equation:

Q O
CH3SCH3 ~ ~ CH3SCH3~ CH35CH3 tDMS) (DMSO) tDMSO2) is essential to life forms and a minimum amount of methylsulfonylmethane in the daily diet is important, if not essential, for good to optimum health of man and lower vertebrates.
To understand the historic role of methylsulfonyl-3s methane in life processes, one should begin at the begin-ii81X3 ning. From the primoridial soup of life resident in the ancient seas, long before even the simplest terrestrial life forms appeared, algae and later phytoplankton pro-duced organic molecules which released dimethyl sulfide to the atmosphere, an on-going process to this day. These simple forms of life, living in the upper or surface layer - of the earth's oceans assimilated and converted inorganic sulfur into diverse organic molecules, mainly terniary dimethyl sulfonium salts. These terniary salts, by enzy-matic and physical means, are broken down to methyl sul-fide. Exemplary of these salts is dimethyl-beta-propio-thetin, (CH3)2S CH2CH2COOH, which appea~rs to be the most common organic sulfur containing molecule in marine plant life, (10~ or more of the dry weight of some organisms).
Dimethyl sulfide, a virtually water insoluble molecule which is even less soluble when "salted out" from marine waters, passes to the atmosphere in quantities sufficient to supply the sulfur needs for all terrestrial life forms.
Volatile, non-polar dimethyl sulfide moves to the upper atmosphere, sometimes called the o~ione layeE, where, catalyzed by sunlight, it is oxidizedi.to the hydroscopic dimethyl sulfoxide ~DM50) andi to methylsulfonylmethane.
Both polar compounds dissolved in atmospheric moisture are delivered by rain to all land masses. Plant roots rapidly absorb and a¢cumulate surprisingly high levels of these compounds, as determined by spe¢trophotometric and radio-tracer techhniques. The stable end products in plants, are methylsulfonylmethane and methionine, an essential amino acid, as well as other sulfur containing compounds naturally occurring in plants. A number of recent publi-cations report that there is not enough hydrogen sulfide in the atmosphere to satisfy minimum cycle requirements and support this sulfur transport mechanism.
Challenger and Hayward reported in 1954 on the presence of dimethyl sulfonium salts, all precursors o i8i~3 methyl-S-methanes, in many marine and terrestrial plant forms serving as animal food. Since then, many scientific articles report on the natural occurrence of the methyl-S-methane series and the most stable member of the series (methylsulfonylmethane) in virtually every vege-table, nut, fruit, meat, fish and beverages as well as coffee, beer, tea and milk.
Metabolic sulfur was as important to life forms hun-dreds of millions of years ago as it is today. Before life "invented" the complex sulfur donor methionine (or cysteine), primitive life utilized the simpler methylsul-fonylmethane and its precursors. Blue'green algae, which is found together with primitive bacteEia ~n the earliest pEecambrian fossil Eemains, still grows wiaely today in lS the earth's surface wate~s and continues to pEoduce DMS, helping to balance the sul~uE equation~ ~f ~fe. Consi-deEin~ that eaEly li~e was progEamme~ to use methyl-S-methanes, one can understand why higher foEms of life are genetically progEammed to employ methylsulf-onyl-methane as a SUlf'UE donoE . TheEe~OEe, methylsul~onylmet~ane is as acce~table an~ as assimilab~e t~ modeEn life foEms as NaCl o~ water and thus presents an extEeme~y low to~icity profile to at least the higheE orms of life.
Methylsulfonylmethane and its precursors are as necessary for a good diet as is adequate potassium. The methyl-S-methane series, at food levels of up to about a hundred milligrams/day, supplies already normal, healthy tissue with maintenance levels of sulfur; with methionine and cysterine degradation products also contributing though apparently not as directly nor as easily in. It is interesting that some forms of life can convert methionine to methylsulfonylmethane as well as the reverse synthesis sequence.
A number of biological effects of methylsulfonyl-methane are described in my copending patent applications 1~ ~i81~3 and issues patents cited above, as is the intentional ingestion of methylsulfonylmethane combinations as foods or flavorant ingredients thereof. The effect of high levels of methylsulfonylmethane ingestion in favorably altering the course of abnormal or disease states is believed to depend primarily on actions of the intact molecule. The major differences between the use of methylsulfonylmethane as a food and as a normalizer of biological function is the concentration and amount employed, dosage forms, and routes of systemic entry. As a food, methylsulfonylmethane plays an important role in the multitude of sulfhydryl (-SH) and disulfide t-S-S-~disruptions, destructions and repair associated with nor-mal life processes. Systemic availability of methylsul-thanQ fOE sulur donat}on; to repair and restoretissue damaged covalent disulfide bonds and syntheslze having sulfhydEyl gEoUpS critical to reactivity, is thus a basic nutEitional requirement.
hs with so many constituents of natura~ ~oods, exc~sg amountg of methylsulonylmethane ae excEeted~
unchanged f~om the body, the excretion Eoutes being the feces, the Eenal pathway and through the skin. Orally ingested methylsulfonylmethane is stored to some degee in various organs, presumably banked for future sulfur needs of the body. The skin excretion route is unusual, parti-cularly since about one-third of a given oral dose can be found in the perspiration. Like NaCl, excretion depends somewhat on perspiration rate. The accumulation in and excretion of methylsulfonylmethane from the skin is believed to account for its cosmetic effect, viz., more youthful appearing, pliable, blemish-reduced skin.
Chemical and radiolabeled sulfur (35-S) assays can be used to determine the extent to which important biomolecules as heparin, insulin, co-enzyme A and other -SH bearing enzymes, biotin, methionine enkaphalin, human growth ' I' /
i8~2~3 factor, hemoglobin, calcitonin, fibrinogen, muscle protein and other compounds derive their thiol (-S-) and disulfide (-S-S-) groups from methylsulfonylmethane and the possible preference of methylsulfonylmethane over S-content amino acids as the donor with such synthesis.
The word "food" broadly means a nutritive material taken into an organism for growth, work, protection, ~repair, restoration and maintenance of vital processes.
Therefore, all animal life needs a continuing supply of food and ¢annot survive for long without it. However, food can also cause poor health and disease. Thus, r,! balanced food intake or balanced nutrition are better definitions than "food" for the nutritional factor essen-tial to good health. "Balanced food" implies that not only are all of the elements of good nutrition present, they are available in ample amounts or supplying the body's needs. Based on my findings with methylsulfonyl-methane to date, a balanced ood intake requires signifi-r~ cant amounts of methylsulfonylmethane as a metabolic sulfur source, since all evidence suggests that no otheringredient OE combination thereo, including methionine, cysteine, cystine and degradation products thereof, ful-fills the role of methylsulonylmethane.
The present invention relates to compositions and 25 methods for replacing or supplementing methylsulfonyl-methane, a natural but fugitive ingredient of food.
Methylsulfonylmethane is lost from natural foods by vir-tually every known method of processing because although stable, it is quite volatile. It is, of course, absent in 30 synthetic food additives, dietary mineral compositions, food substitutes and most fillers used to dilute or modify foods. It is also absent in "comfort" products, such as tobacco products, various alcoholic beverages, and cosme-tic products such as toothpaste, mouth washes, breath 35 sweeteners, and other similar agents that directly contact ` i l;~i8~2~3 the mucous membranes of the buccal cavity and in some cases the entire respiratory tract, as in the case of cigarette smoke.
Using conventional analytical procedures, one can readily determine the naturally occurring methylsulfonyl-methane (and/or its precursor) content of the cooked, processed and/or stored food and how it compares with the corresponding unaltered or natural food. For example, unp~ocessed milk from cows fed a nutritionally balanced feedstuf and permitted to field graze typically contains about 2-5 ppm of methylsulfonylmethane. In cont}a-distinction, the methylsulfonylmethane'content of unpro-cessed milk from cows fed dried animal feedstuffs and of milk and milk products which have been p~ocessed and pasteu~ized is negligible. One ¢an readily calculate the amount of methylsulonylmethane needed t~ restoEe milk, buttermil~, cream, yogurt, etc., to their "natural"
levels. This is most conveniently accomplished at the bulk level, just beore the milk ~E d~iry pEoduct iS to be bottled or packaged. 5ince otheE nutEit~onal factors, such as Vitamin D, are customaEily adae~ to mil~, the ! technology and equipment for such additionis is conven-tional and readily available.
Many of the fEuits and vegetables customarily consumed by humans contain approximately 1-4 ppm by weight of methylsulfonylmethane when freshly harvested. However, during processing, e.g., canning, most of the methylsul-fonylmethane is lost. As in the case of dairy products, it is convenient to add the amount of methylsulfonyl-methane required to restore it to its natural value to theprocessed product just prior to packaging or use.
It is apparent from the discussion above that superior nutritional benefits are obtained when methyl-sulfonylmethane is added to foodstuffs that do not require further processing, particularly processing requiring ;8123 extended periods of heating or drying. Thus, it is pre-ferable that methylsulfonylmethane be added to dairy pro-ducts, canned fruits, desserts and other confections, vegetables, etc., wbich are not heated or which require only a minimum of warming prior to consumption.
Foodstuffs Methylsulfonylmethane has, since 1983, been sold both as a food and food supplement for human consumption and its utility for such purposes has extensively been established. Its utility as a restorative additive in foodstufs adapted for consumption by human beings or other animals has similarly been confirmed in a variety of species.
Examples of processed foodstuffs adapted ~or human consumption which typically have naturally occurring methylsulfonylmethane levels below about 0.25 ppm, are pasteurized milk and milk products, brea~fast ce~eals, ; bread and other bakery produ~ts, canned fruits, vege-tables, meats and fish and dried meats and fish.
Examples of processed foodstuffs adapted for domestic animal consumption which typl~ally have naturally " occurring methylsulfonylmethane levels below about 0.25 ppm are dry, semi-dry and canned cat and doq foods;
multi-ingredient feeds adapted for consumption by herbi-vores, poultry, swine, etc.
All of the foregoing products are processed in a manner which includes a heating and/or drying step which reduces their naturally occurring methylsulfonylmethane content to below about 0.25 pm. Methylsulfonylmethane can be admixed therewith after the aforesaid heating and/or 30 drying step. e.g., after cooking in an open vessel at or above 100C, to bring the methylsulfonylmethane content thereof to about 0.01 to 20 ppm, preferably about 1 to 15 ppm, in the case of foodstuffs intended for human, dog or cat consumption, and about 0.01 to 20 ppm, preferably 1 to i 1~6~ 3 ( 10 ppm in the case of feed intended for consumption by a species of farm animal.
The methylsulfonylmethane can in some instances be admixed in crystalline form with one or more ingredients of the foodstuff as part of a final dry mixing step or as an aqueous, alcoholic or other ingestible solvent solution thereof, e.g., by spray mixing. Because of its volatility the foodstuff should not be subjected to an open-container - cooking or drying step after the methylsulfonylmethane is admixed therewith. In the case of dEy foodstuffs, the volatility of methylsulfonylmethane can, if desired, be ~' counteracted by encapsulating or coating the individual particles of methylsulfonylmethane prior to its addition to the foodstuff with a continuous coating, e.g., a lS natural waxy or synthetic polymeric film, which is dis-solvable or removable in the digestive system. Techniques for coating moisture-unstable products intended for ingestion, to protect them Eom the adverse effects of ~i atmospheric moistuEe and/oE oxygen, are well-known in the pharmaceutical arts and can be em~loyed to inhibit the loss of the methylsulfonylmethane from the foodstuff prioE
~, to its ingestion by evaporation. Loss o the methylsul-fonylmethane from wet processed foodstuffs products can be reduced by conducting all heating steps and storing the pEocessed foodstuff in a sealed container In addition to or alternative to being administered in admixture with one or more of the foodstuffs ingested by the animal, as described more fully elsewhere herein, methylsulfonylmethane can also be incorporated into the diet of humans and lower animals by ingesting the crystal-line methylsulfonylmethane or a solution, e.g. aqueous, thereof separately from other foodstuffs, preferably, in unit dosage form, e.g., as a tablet, capsule, dragee or pill, as such or in admixture with the usual pharmaceuti-cally acceptable excipients, diluents, tableting aids, 12 ~ 8.~Z 3 etc., with tablets and capsules being preferred, especialy those containing from 100 mg to 500 mg methylsulfonyl-methane each.
Although human beings are the preferred recipients, S other vertabrates, including mammals, e.g., domestic animals, such as horses, cows, sheep and pigs, pets, e.g., - cats, dogs and fish, and wild animals kept in zoos, and fouls, e.g., chickens and other poultry, can be treated according to this invention. soth small children and adults, including geriatEics, gain a more beneficial balanced diet when methylsulfonylmethane levels match natural, unprocessed foods.
Although this invention is directed pri~arily to methylsulfonylmethane-~ontaininq ~oodstuf, methylsul-lS fonylmethane is useful in other oral forms, e.g., mouthwashes and toothpaste preparations, because o~ its chemi-cal and light stability, low toxi~ity, good solvency, WateE solubility and dispersibility.
1:!Methylsulfonylmethane, alone or in combination wlth an appropEiate phaEmaceutically active agent, has demon-stEated usefulness when introduced into other body cavi-!ties, e.g., vaginally and rectally. Methylsulfonylmethane can be introduced into the lungs and bronchial tree as an aerosol o a solution thereo or as a sublimate produced by heating, which can be inhaled.
Since methylsulfonylmethane has an additive flavoror flavor enhancing property, e.g., for chocolate, soy sauce, salt, sweet vermouth and other alcoholic beverages, carbonated cola beverages, rye bread and other baked goods, it can be included in condiments and admixed or co-crystallized with ~aCl or other particulate flavorings and condiments. Methylsulfonylmethane can also be safely administered by intravenous or parenteral injection.
Additional benefits are seen when methylsulfonylmethane is provided in combination with the water-soluble vitamins.

( ( 12~i8123 Animal Feed The animal feed aspect of this invention can be practiced in a number of ways. For example, the methyl-sulfonylmethane can be added to low moisture corn (approximately 14% moisture) at levels in the range of 15x10 4% to 3.0 %, usually 0.01 % to 1.0 %. Inasmuch as methylsulfonylmethane is a solid, the addition can be carried out in a batch feed mixer.
- After the corn has been treated, it can be used as su¢h as an animal eed or it ca~ be stored and used at a later date or it can be mixed with otheE ingreaients, e.g., alfala meal, soybean mea~l, m~inerals and vitamins.
The resultant mixture can be used as such as an animal feed or it can be pelleted and the pellets employed as an animal eed.
One method of preparing pellets is to gEind corn, alala meal, soybean meal, minerals and vita~ins, add steam to bring the moisture aontent up to 16~ wateE and then allow the mixture to stand and cool so tbat the inal moisture aontent i5 around 14%. Methylsulfonylmethane ls added to thls mixtuEe, preerably beore pelleting in proportions suiaient to give a mixed feed containing the desired conaentration o methylsulfonylmethane. The corn admixed with the methylsulonylmethane can be used as 2S whole keEnels OE it can be craaked or gEound and used as suah OE in mixed feeds. In aase the product is to be used without lengthy storage, the methylsulfonylmethane content can be as low as 15x10 4 ~ to 3.0 %. Because of the volatility of the methylsulfonylmethane, if the corn or feed is stored prior to use, the methylsulfonylmethane content is preferably about 0.01% to S%.
The methylsulfonylmethane can also be administered to the animals in the form of a solution in their drinking water, e.g., 0.01% to 3%, preferably 0.1% to 2~ by weight.
The methylsulfonylmethane can also be added to the - ~2681~

animal feed immediately prior to feeding time, e.g., by spraying a solution thereoE into the feed or stirring crystalline methylsulfonylmethane into the feed in amounts which will provide the desired ingested amount.
The animal feed aspect of this invention is parti-cularly important where it is desired to improve the overall appearance of or maintain the health of herbivor-ous animals, especially bee cattle, dairy cattle, hogs, horses, sheep, goats and owl. It is parti¢ularly useul edueing the inciden¢e o stress-Eelated ~eaths~, e.~- r due t~ ¢lose ¢oninement.
~d The methylsuIf/onylme~hane is us~ally ~!E~,i~e~ in the aninmal's normal eed rations, peEl~ea~ thEoughQut the day or on suc¢essive days, or both, e.g,., f~E ~ t~ 21 lS days or even longeE. The daily f~od ration appropriate ~OE the animal being fed is supple~ented wit~ an amount of methylsulfonylmethane calculatea to ¢orrespond to a pre-determined amount per total body weight o the animals ;;i being ed. The exact amount of methylsulony~methane
2~ ingested each day is not always cEitical/ particularly when methylsulfonylmethane a~ministration ~ o~eE a~
extended period of days, becaus~ the ingested methy~sul-~onylmethane accumulates in the body tlssues and fluids, i.e., reaehes an effeetive titer. MethylsulfQny~-2~5 methane-supplemented rations providing levels o as low as 0.~-1 mg~kg animal body weight are sometimes effeet~e an~
~evels as hlgh as 300 mg/kg body weight or moe a~e well tolerated. The usual target level per individual animal is about 0.2-2.0 mg/kg body weight preferably 0.5-l.O mg per kg body weight. Total daily supplements corresponding to up to about l gm/kg body weight or more, are preferably employed, depending on the degree of deficiency. Healthy animals often have methylsulfonylmethane blood levels of at least l ppm, and desirably, enough methylsulfonyl-methane is provided to raise blood levels to above l ppm.

-- 12~i81X3 The oral ingestion of amounts of methylsulfonylmethane in excess of that required to elevate blood levels is not harmful because of the extremely non-toxic nature of methylsulfonylmethane.
Because methylsulfonylmethane is naturally present in the body fluids and tissues of animals, its mode of action resembles that of a vitamin-like dietary supple-ment. Although methylsulfonylmethane has not yet been established to be a vitamin, at least a vitamin deficiency-type disease has not yet been proved to occur in animals with abnormally low methylsulfonylmethane blood levels, it does have a vitamin-like moderating or normalizing activity correlation between abnormal physiologlcal symptoms and low methylsulfonylmethane blood levels. WhetheE this is due to the inability o~ such animals to adequately store methylsulfonylmethane from natuEal souEces thereof, to inadequate amounts o methylsul~onylmethane in the diet of those animals or the deeletion of the methylsulonylmethane usually present in the bo~y as a Eesult of the abnormal condition, is not known. WhateveE the reason, the oral ingestion of ,~ methylsulfonylmethane in sufficient amounts will ulti-mately bring methylsulfonylmethane levels to or above those usually present in healthy animals and will ameliorate a vaEiety of symptoms associated with stress.
Like vitamin C, glucose and other substances normally present in animal diets, methylsulfonylmethane exhibits remarkably low acute and chronic toxicity in the hosts diet. Primates with high (greater than 1 gm/kg body wt.) methylsulfonylmethane blood levels for at least two years lack evidence of methylsulfonylmethane toxicity.
Although methylsulfonylmethane is found as a natural constituent of foodstuffs, like vitamin D, the principal supply in animals is believed to be synthesized by the body using dimethyl sulfide or one of its naturally 81Z~3 occurring precursor salts as commonly found in meat, fish, veqetables and fruit. Too low a body concentration of methylsulfonylmethane results in adverse physical and psychological stress, tissue and organ malfunction, fatigue and increased susceptibility to diseases.
Based on the excretion rate from young compared with older animals, methylsulfonylmethane appears to be present in lowering concentrations with increasing age.
Gederally, with maturity, there is less than 0.5 ppm }0 methylsulfonylmethane in the humoral fluid. This may explain why methylsulfonylmethane has proved generally moEe useful as a dietary supplement with mature animals~
in whom naturally occurring levels of methylsulfonyl-methane, generally are lower than optimum for providing 1~ optimum protection of the OEganiSm fEom StEeSS challenge.
A conventional diet does not supply the~ minimum Eequ~re-ment ~OE o~timum~ health. FOE example~ unproeessed mil~, one natuEal SOUEC~ ofi methylsulfonylmethane, contains only about ~-5 ppm depenaing o~ the so~Ece~ ~Q obtai~ an~
~Q Eetain a minimum bloo~ level of methylsulfonylmethane o~
about 1 PPmF animals would be requiEed to ingest an !1~' impEa~tically laEge amount of this OE any other single unpEo~essed food pEoauct. AccoEding to this invention, ~h~ diet of a methylsul~onylmethane-deicient animal is 2~ su~lemented with sufficient methylsulonylmethane to provide blood levels of more than 1 ppm and, where health is threatened, a level of 10-20 ppm or higher.
Additional benefits are seen when methylsulfonyl-methane is provided in combination with the water-soluble vitamins.
Conventional feedstuffs for meat producing animals comprise supplemented complete or basal animal feeds or, alternatively, premixes for preparing such feeds. The carrier or basal feed is usually hay or corn derived but may include dried fermentation residue, alfalfa, cotton-~ i8~

seed, barley meal, soybean meal, corn meal, rice hulls, molasses, mineral salts, vitamins, silages, beet pulp, citrus pulp, fish meal, oats, rice bran, milo, sesame meal, milk or other standard animal feed ingredients. In premix compositions the other ingredients are mixed in high concentration with a carrier ingredient which is usually desirable in the complete feed such as soybean meal, corn oil, ground corn, barley, mineral mixtures such as vermiculite or diatomaceous earth, corn gluten meal, corn distillers solubles or soyflour. As examples of the livestock feed normally ingested per meat producing animal per day are: sheep 3-4 lbs., feed lot~steer 20-25 lbs., swine 1-8 lbs., poultry 0.03-1 lb. The methylsulfonyl-methane contents of these animals feed is adjusted to provide the desiEed mg/kg body weight methylsulfonyl-methane daily ingestion rate.
Dairy cattle typically are ed two different types of vegetable ~eed, the irst roughage including hay and~
corn silage and the second, a supplemental ration usually containin~ ~ngEedients of the type listed~ above. In the case of an average dairy cow, this supplemented ration ! migbt be within~ the Ean~e of 10 to 20 pounds per day.
Feed intendedi for chickens would not contain added roughage. The ratio o starch to protein would depend on 2S whetheE the bird is being raised for meat or is a hen producing eggs.
Also well known and readily available commercially are pet foods for dogs, cats, hamsters, etc., and fish food, etc.
As previously stated, methylsulfonylmethane when included in animal feed rations is useful as a flavor enhancer, as a health maintainer and in preventing stress death in the animals.
Stress deaths are a well known phenomena for some species of animals, especially chickens, because of the l~iB1~3 crowded manner in which they are raised and transported and the generally rough treatment given to them in trans-ferring them from one area to another; turkeys, because of their temperament; and fish, especially species of tropi-cal fish which are normally sold for aquariums, because oftheir extreme sensitivity to changes in the composition of or temperature of their water. Methylsulfonylmethane is particularly useful in reducing the incidence of stress-related deaths when administered daily for from 7 to 90 days, preferably 14 to 28 days prior to the animals being exposed to the death-inducing StEeSS, and during the period of such stress, e.g., at dosages from about 0.01 to 10 mg/kg, preferably from about 0.01 to 5 mg/kg body weight per day.
The following aEe pharmacological uses foE methyl-sulfonylmethane in addition to its use in foodstuffs as described heEeinabove:
; 1. Reducing the adveEse response t¢ inhalant ~; alleEgens. This a¢tion may be due entiEely or in part to a physical bloc~ing action. ~abeled 35-S dimethyl sulfone binds tightly to the suEface ~ mu¢ous membEanes and by ' aUtoEadiogEaphy, the membEanes appears to be ¢oatedi, as with a paint.
2. Controlling problems associated with gastric hyperacidityl e.g., relieving epigastric pain.
3. Providing relief from chronic constipation.
4. Reducing or eliminating hypersensitivity pro-blems associated with oral medications, such as non-steroidal antiarthritic agents. This effect may be the result of the interaction of the methylsulfonylmethane with plasma prostaglandin F2.
5. Providing relief from the symptoms of lung dysfunction, e.g., by plasticizing effect on the membrane surface of the lung involved in gas exchange.
6. Controlling parasitic infections associated with 81'23 the intestinal or urinogenital tract, e.g., those caused by giardia or trichomonads. Methylsulfonylmethane also has a beneficial effect in the treatment of disease con-ditions caused by a spectrum of other micro-organisms.
7. Mood elevators, e.g., for the terminally ill.
8. Improving the chemical profile of arthritic patients, e.g., providing relief from pain and stiffness, reduced swelling and inflammation, coupled with a return o~ blood chemistry towards normalcy, for example, a RH
titeE drop from 600+ to 300 OE lower.
9. Relievinq leg and back cramps, muscle spasms and general soreness, particulaEly in the qeriatric patient, and in the premieE athlete ater completion stEess.
10. Reduction in hypeEtension.
11. Promoting remîssion in myositis ossificous geneEalis ~a rare, genetic~autoimmune dysunction).
t2. ImpEoving the overall health of domestic and ~arm animals, e.~., dairy an~ beef ¢attle, horses, pigs, r~; sheep, qoats, chickens and tuEkeys whose caloEic intake is ~redominantly or exclusively pEocessed food Eather than gEoWing gEasseS an~ plants.
13. Reducing the incidence o~ stEess deaths in animals Eaised and~oE shipped in crowded or otherwise stressful conditions.
Leg CEamps Methylsulfonylmethane has the surprising ability to reduce the incidence of or eliminate entirely muscle cramps, leg and back cramps, particularly in geriatric patients who experience such cramps at night and after long periods of inactivity, e.g., while sitting, and leg cramps in athletes, e.g., runners, football, basketball and soccer players, who experience severe leg cramps during participation in their sport. Ingesting methyl-sulfonylmethane, either in pharmaceutical composition form or in admixture with one or more foodstuffs for from 1 to ~ i81~3 -90 days will reduce the incidence of such cramps or eliminate them entirely.
Parasitic Infections Methylsulfonylmethane has an ameliorating or curing effect on a variety of parasitic systemic microbial infections. Efficacy can be determined by in vitro test-- ing to determine growth inhibition or killing of the specific organism by exposure to methylsulfonylmethane at various concentrations in an otherwise acceptable gEowth-maintaining in vitro media for the organism. If , inhibition or death of the ~Eganism OCCUES when expose~ to methylsulfonylmethane at con¢entrations below about 100 ppm, the methylsulfonylmethane will exhibit in vivo activity against that organism. Examples of parasitic g infections susceptible to treatment with methylsulfonyl-m~thane are those commonly assoc1ate~ with infection o~
the intestinal or urinogenital tract, e.g., Nematodes, Trichomonas vaginalis, GiaEdia, EnteEobius and other intestinal worms, syste~ic infections by Histoplasma cap-sulation, Cocidioides, ~oxoplasm and other in vitrosusceptible organisms.
Intravenous Administration In ~.S. 4,296,130, I teach that methylsulfonyl-methane is so inert and non-toxic that aqueous solutions thereof can be used as a blood diluent. In healthy humans or other animals baving adequately high methylsulfonyl-methane blood levels, methylsulfonylmethane is in fact n inert" in the sense the term is used in that patent.
However, in acutely ill patients, dramatic beneficial benefits are often obtained by the intravenous admini-stration of large doses of methylsulfonylmethane. For example, rheumatoid arthritic patients suffering from a flair-up of the disease which produces intense pain or crippling swelling of the joints or both achieve prompt relief, even those patients who obtain only minimal or delayed benefits from oral ingestion of methylsulfonyl-methane.
Apparently, when a patient is in an acute stage of intense pain-producing disease, such as rheumatoid arthritis, osteoporosis, degenerative disc syndrome, an autoimmune disease or metathesized carcinoma, which pro-duces intense pain, the relief from pain from oral inges-tion of methylsulfonylmethane is sometimes too subtle or taKes too long for the patient to obtain reasonably pEompt subjective benefits thererom. In contradistinction, intravenous administration o methylsulfonylmethane gives pEompt, i.e., within hours and often within minutes, relief Eom pain and often dramatic benefits, e.g., a significant reduction in the cEippling efects o lg, EheumatoL~ aEthEitiS, TheEefore, in one aspect this inve~tion Eet ates to a method for Eapidly ame~ioEatin~ at least the pain asso-ciated with an intense pain-pEoaucing disease by the intravenous administEation of methylsulfonylmethane in an amount effective to amelioEate the pain.
The amount o methylsulfonylmethane intEavenously !1~ administered can vaEy substantially begau~e of' its tack of toxi~it~ an~ ad~eEse side efects. Indivi~ual dosesl ean ~ary f~Eom~about 0.~1 to 2 gm/kg, preferably ~rom about 0.1 to 1 gm/kg, on a body weight basis, the usual dosage range is about 0.25 to 0.75 gm/kg, preferably about 0.5 gm/kg.
When large amounts are administered, e.g., in the order of 1 g/kg of body weight or more, i.e., infusion of 5 % to 10 ~ solution of methylsulfonylmethane in water, physiological saline or S~ dextrose is preÇerred. The rate of administration is preferably no greater than about 1 gm/kg/hr, although infusion rates as high as 2 gm/kg/hr are tolerated by patients, except for light-headedness of the type experienced by some blood donors is experienced by some patients at this rate.

lZ~BIX3 Because methylsulfonylmethane is very rapidly excreted, the intravenous administration can be repeated frequently, e.g., every 12-24 hours. However, one i.v.
administration often suffices to achieve amelioration of pain and other symptoms, which remission can be maintained for weeks or months with orally ingested methylsulfonyl-methane.
Without further elaboration, it is believed that one skilled in the art can-, using the preceding descrip-tion, utilize the present invention to its fullest extent.The following preer~ed spe¢ific embodiments are, there-ore, to be construed as merely illust~ative, and not limitative of the remainder o the disclosure in any way whatsoeveE. In the following examples, all temperatUEeS
g are set forth uncorrected in degrees Celsius; unless otherwise indicated, all parts and percentages are by weight.
Example I - Human Food DuEing the cooling step of a conventional continu-ous milk paSteuEizatiOn pEoceSs, inject a sterile 25 aqueous solution o methylsulonylmethane into the pasteurized mil~ at a Eate which imparts a final concen-tEatiOn thereo in the milk of about 15 ppm.
Example 2~ - ~uman Food Incorporate prioE to cooking, along with the NaC1, sugar or any condiment which is added to a vegetable or fruit cooked under pressure in a sealed can, e.g., corn, peas, tomatoes, green beans, peaches, pears, pineapples, apple sauce, etc., an amount of methylsulfonylmethane which provides a concentration thereof in the cooked pro-duct of about 5 ppm.
Example 3 - Equine Feed Calcium/phosphorous balance is critical in the horse, where these elements comprise roughly 70~ of the mineral content of the horse's body. Calcium deficiency, ~;8~

or the reverse, viz., phosphorous excess, is undesirable.Phosphorous excess in feed will decrease intestinal absorption, resulting in lowered blood plasma calcium.
One result is a stimulation in the dietary deficiency condition called nutritional secondary hyperparathyroid-ism. Calcium denied for bone development results in an enlargement of structurally defective fibrous tissue. In horse leg bones, it is called epiphysitis when stress inflammation is presented.
Two colts and our illies were studied, all &b diagnosed as having nutritional secondary hyperpara-thyroidism with obvlous epiphysltis. Each was provided with 12 grams o methylsul~onylmethane twice daily in a bran/molasses blend intermixea with their standard dry feed prior to eeding. The supplemented feed was well accepted. All signs and symptoms oE this nutritional deficiency disease was coErected in ~rom seven to ten days. Conventional tEeatment for correcting dietary calcium deficiency requires a minimum o 60-90 days before relie from in1ammation is obtained. Except for the added methylsulfonylmethane, theEe was no change in the diet o these seven horses. The added dietary factor corrected this easily recognizable dietary deficiency in all o the horses.
Example 4 - Equine Feed A valuable breeding mare, treated for a respiratory infection developed bilateral fibrinous pleuritis, easily heard wi h auscultation of the chest. After six weeks therapy with a combination of conventional antibiotics and anti-inflammatory drugs, there was little if any improve-ment. Conventional therapy was terminated. ~ethylsul-fonylmethane was added to the diet of this refractory case (24 g, twice daily, over a period of 5 days). This was the only special treatment given. sy the fifth day the animal no longer demonstrated pain and the shallow, rapid ~ ; 12~8~ ( i"

breathing returned to normal. Auscultation of the chest was negative. This horse was followed over the next two years and was judged normal and healthy.
Example 5 - Methylsulfonylmethane in Tobacco S Distribute methylsulfonylmethane in the tobacco used to provide cigarettes at the rate of 100 ppm by weight by spraying the tobacco just prior to being formed into cigarettes with a 10 % ethanolic solution of methyl-sulfonylmethane at the rate o one ml/kg.
The inhaled smoke rom such ¢igarettes includes sublimed msthylsulonylmethane, which counteracts the adveEse efect o~ the smoke on the lung mucosa. Also, a significant numbeE o smo~eEs find the 1avoE and taste of the cigaEette more desirable than otherwise identical lS cigarettes lac~ing the methylsul~onylmethane Example ~ - ~ail eEowth In An~mals ~ ate of nail growh is a~ ~ndl~ation o the overall health o an animal. To de~eEmine the efect of methyl-sul~onylmethane on nail gEowth, tWQ: litteE mate emale labradoEs, age ~.S months, weEe maintained~ in side by side straw bedded ca~es. BeoEe any testi~g, the ront paws of ~, each dog weEe embedde~ in paEtially set plaster o paris, allowing the animals to exert full body weight, thereby obtaining good cleaE impEeSSions o paw pads and nail length.
Each dog was fed Purina dog chow and water ad lib for 45 days. One of the dogs, (Animal A) had no ration change and the other (Animal B) was supplied only with water containing 5% of methylsulfonylmethane dissolved therein. After 45 days, plaster impressions of the front paws of each dog were again taken. Once the plaster had fully hardened the pre- and post-testing castings of each animal were compared. The straw bedding protected both animals from normal nail wear. On visual examination, the nails of Animal B, the animal receiving methylsulfonyl-methane in its water, were obviously longer. Upon comparing the castings it was seen that Animal B had nails that averaged about l/8th inch greater length than those of Animal A.
The hair, horn, and nails of animals can contain 5%
or more sulfur based on elemental analysis. This test indicates that the sulfur of methylsulfonylmethane, roughly 1/3 the molecule's weight, is utilized benefi-cially in stimulating at least nail growth.
Example 7 - Animal Coats ; The coats of animals A and B of Example 6 were examined by thEee individuals. Each j~dged the coat of Animal B to be supeEioE, based on thickness and the shiny ap~earance genera-ly associatedi with good health.
1~ xample 8 - Animal Coats ~ en 4-wee~ old guinea pigs were housed in indivi-dual meta~ cages in a standaEd tem~eEatuEe room with a l~-houE light~daEk cycle and ac~limateai OVeF a 5-day period of feed1n~ PuEina guinea pi~ chow with wateE ad 2~
On day six, five animals weEe maEked on the belly with redi and the other five with blue water-insoluble ink.
The mRrks were not visible when the animals were observed from above. Each animal afteE marking was retuEned to its cage and a corEespondiing redi OE blue tape affixed to the animal's watering bottle. The red marked bottles were maintained with tap water and the blue marked bottles were filled with tap water containing 2 wt.% methylsulfonyl-methane. During a 28 day period, the animals were fed and allowed access to their water or water + 2% methylsul-fonylmethane, respectively, ad lib. On day 28, the - animals were placed in common confinement on a well lighted table. Four individuals, totally unfamiliar with the test and its purpose were asked to evaluate the coat of each animal. Animals at each evaluation were removed -"` 12S81Z3 by the evaluator and placed into one of two groups based on better or poorer quality of the animal's coat without seeing the color on the animal's belly. Three of the four evaluators quickly selected five animals with superior coats, all of which were later determined to bear a blue belly mark, i.e., the methylsulfonylmethane treated group.
The fourth evaluator selected three animals with a blue belly mark as having superior coats but concluded he could not distinguish better from the poorer with the remaining seven animals. Despite the failure of one evaluator to ,~ cleaEly distinguish all animals given methylsulfonyl-methane from the controls, the testing~demonstEated that a generally visible improvement is seen in the coat of a guinea pig having methylsulfonylmethane as a~ added food~
in its Eation.
E~ample 9 - Stress Death in Chickens Feed bEoile chic~ens, no more than a few days old, WeEe fed one o two dlets~ viz., stan~ard fee~ ~r s~an~aEd ~'S'i feed plus 0.2 wt.~ methylsulfonylmethane f~oE a p~Eio~ o 30 days. There will be a significant d~ffeEence between the stEess death rates in the two lots duEin~ that peEiod.
pi, With those fed unmodified feed, the death Eate wi~l be noEmal, viz., about 10~, whereas with methylsulfonyl-methane modi~ied feed the death rate will be less than 1~.
Example 10 - Stress Death in Fish Fish of any species demonstrate stress death in crowded conditions. Commercially valuable species, such as salmonids, are very prone to stress-death during con-finement in hatcheries or aquaculture farms.
62 Goldfish, about 2 inches long, were divided into two 31 population lots and placed in acclimated aquariums (2) maintained at 50F. On receipt of the fish, two small one gallon aquariums were filled with tap water and stablized for S days by aeration with an aerator/filter combination connected to a common aquarium air pump. Air i8~3 delivery during the teqt period was standardized at 100 ml of air per minute. From a 1 oz. package of ~Wardleys"
goldfish food two 10 gram samples were removed. One sample was untreated and the other was moistened with S about one ml of pure ethanol containing 0.2 gram methyl-sulfonylmethane in solution. The feed absorbed all the methylsulfonylmethane (the lot after air drying for 48 hours weighed 10.2 grams). Both feeds were pulverized to a coarse powder suitable for feeding small fish.
The 31 fish in each of the two holding aquariums were identiied as bateh A and bateh B. During the !- acclimatisation and test periods the batch A ~ish were fed 0.5 gram of untEeated ~Wardleys~ food onee daily. Bateh B
fish were ed 0.5 gram of the ~eed containing the methyl-sulfonylmethane auEing the a~l;matisation and test peEiods. NeitheF batch A nor B consume~ all o~ the feed as some e~entually colleete~ Ln the fibe~Eglas~ filteE.
~oWeVeF~ moat of~ eaeh feeding was consume~ i~ the ÇiEst S-l~ minutes afteE delivery. During the 5th day, 25 fish ~ 20~ o bateh A were transfeFEe~ t~ one small a~uarium ~designated A) and as fish o~ bateh B.weEe moved to the ~, otheE small aquaEium tdesignate~ B~. ~evre transer, each aquaEium was temperature adjuste~ w~th iee to 41F.
The WateE was~ allowe~ to return to ambient, e.g., to 5~F, afteE the fish were a~ed to the tank. The ~ish of b~t~
batches were thus subject to a total of 9F temperature change, which stressed the fish. Feeding was resumed after starving them for one day in the small tanks. By day ten, (five of them in the small aquariums), there had been a total of 11 deaths in aquarium A (control) and one death in aquarium B.
The combination of impressed negative temperature, tank transfers, marginal oxygenation of the tanks, and coneinement of a beginning population of 25 fish/gallon aquarium imposed sufeicient stress to kill nearly 1/2 the 1~ ~ 81~:3 .. ..

control fish. The addition of only 2% by weight of methylsulfonylmethane to the feed reduced stress signi-ficantly.
Example 11 - Oral Hygiene Subjects not having professional dental cleaning for at least four-six months and demonstrating minor yet discernable gum inflammation, probably due to plaque irritation, were given either a paste (Colgate tooth pa5te) prepared by combining a commercial dental product with methylsulfonylmethane on a 50/50 w/w basis. Subjects ~i! cleansed their teeth on a twice daily regimen. Pollowing one week use, the oral mucosa of all subjects was free of signs of in~lammation. One subject tT.K., M 22) troubled with recurring canker sores reported freedom from this problem during and a~ter the one month testing was terminated. ~ethylsulfonylmethane, a solvent an~
dispersant in aqueous media, was shown to be an excellent agent al~ne foF cleansing of teeth and the buc~al cavity.
5ub~ects of this test with a viscid- mueo~ naso-phaEyngeal discharge experien¢e a reduction in the visco-sity of the mu~ous and generally a productive cough.
,r, InteEestingly, two subjects with a restricted sense of smell found a sharpening o this sense while methylsul-onylmethane was being evaluated by them in a gargle.
2S Critical observers noted their sense of taste was improved.
Bad breath associated with smoking or food, such as onion and garlic, is reduced or eliminated by cleansing the teeth and mouth with methylsulfonylmethane in water, saline solution or a conventional oral hygiene product.
Example 12 - Maintenance of Good Health 14 subjects of both sexes, all in apparent good health, ages 33-59, were given oral methylsulfonylmethane in amounts ranging from 250 to 500 mg daily which main-tained their blood levels above 1 ppm. These individuals . ~ ( ; ~` 12~81~Z3 were continued on methylsulfonylmethane, taken as a solution in orange juice for periods of from about seven months to over one year. None of the 14 became ill during this testing and each reported feeling better and stronger with increased endurance while methylsulfonylmethane was a part of their diet.
Example 13 - Connective'Tissue and Dermatological Disorders ' Primary and secondary pruritis, acne (including Grade 4), acne rosacea and diverse other dermatological ~,,, problems which are often allergy-related respond favoably to a diet supplemented with methylsu~f~onylmethane.
Pruritis due to various causes and acne respond promptly to diet supplemented levels of about 100-1000 mg per day.
Teenagers found methylsulfonylmethane in cola drinks a pa~EticulaEly acceptab~e satisactory combination when tEeatin~ acn~. With; EoSa~,ea~ vLsua~ impE~vement was much slowe. ~n OQ~ su~eet ~ . t ~ 5~1 ~a~ly,, ingestion of '~;' ' 500 mg methylsulfonylmethane foE at ~east seveEal wee~s was required befoEe telangieetasis diminished.
ExamplQ 14 - Inflammation of the Eye .
~1'!' A 15% solut~on of methy~sulfonylmethane in -, isotonic saline was a soothing treatment for the eye-following aceidental injury due to particulate matter in the eye as dus 0 pollen. A rabbit eye, irritated with aqueous sodium lauryl sulfate, quickly cleared when treated every hour with 10% aqueous solution of methylsulfonylmethane.
Example 15 - Pain Associated With Systemic Inflammatory Disorders Individuals presenting signs and symptoms of pain and inflammation associated with various musculoskeletal system disorders reported substantial and long lasting relief while including from about 100 up to about 5,000 mg of methylsulfonylmethane per day in their daily diet.

,, - - . , :.5,,~ ( Most, trying methylsulfonylmethane first alone and then in combination with ascorbic acid, reported greater benefit with the combination. The combination of methylsulfonyl-methane with ascorbic acid was seen to be particularly useful in correcting night leg cramps. Migrane sufferers have obtained substantial relief at oral dose levels of 50-500 mg per day.
One subject (M.P., F 81), presented chronic arthritis with painful involvement of the lower trunk.
Over the years she had evaluated most new antiarthritic, analgesic drugs with disappointing results. She included methylsulfonylmethane (1/2 tsp. daily)~in her diet and found almost total pain relief by the end of the second week. Ater ingesting methylsulfonylmethane daily at 1~4-1/2 tsp. or about 16 months, the subject is enjoying a substantially pain-free life.
Example 16 - Mental Normal~y In man, mental normal¢y ls demonstrated by alert-~i~ ness with inner ~almness which is not subject to sharp swings ln mood change. Individuals on methylsulonyl-methane generally repoEted increased ale~tness, a plateau of mood changes, and particulaEly very infrequent depres-sion. A ew subjects on medicatlon intermittently for depression observed that methylsulonylmethane relieved depression within hours rather than days, as had been their prior experience with antidepression medication.
Students reported that while taking methylsulfonylmethane, their ability to concentrate is enhanced. Methylsulfonyl-methane therefore is useful in conjunction with CNS
therapeutants. The most useful application for methyl-sulfonylmethane seen to date in the field of mental normalizing is as an aid to the terminally ill, to relieve anxiety and depression.
To a chronically or terminally ill patient suffering from mental depression, administer 1000 mg/kg .~ ` 12~i~12~

body weight of methylsulfonylmethane daily, in tablet or capsule form, dissolved in water or a cold beverage, or admixed in a cold food. Within 12_hours to 2 days, a significant improvement in the mental attitude of the patient will be noted.
Example 17 - Wound ~ealing Four sets of 5 hamsters were subject to scarifica-tion of the right cheek pouch, using standard methodology.
O~e week prior to pouch injury, one set was started on a daily regimen of 0.1 gm/kg o methylsulfonylmethane in the diet of standard hamster eed, a seeond group was given 0.1 gm/kg of methylsulonylmethane plus 100 mg of aseorbic acid in the same feed, a third group was given only 100 mg of ascorbi~ acid in the same fee~ an~ the, last 9EOUp, fed only the feed, was held as eontEol. Dai~y post-s¢aEifi-cation examination was made to determine the Eate of in~ury repaiE. After 36 hours, the animals Eeeeiving methylsul~nylmethane plus vitamin C ~ra~ly had shaEply ; Ee~ueed inflammation about the wou~nds and pEominent healin~ granulation. This baseline result was matched by da~ thEee with ~t~ methylsulf~nylmethane al~ne and ; vitami~ ~ alone tEeate~ subieets. B~ day 4 and 5, contEols (no medication) matehed the healin~ status seen at 36 hours with those animals receiving the methylsul- .
fonylmethane/ vitamin C combination.
Example 1~ - Diet Supplement in Animals Immature laboratory animals, including dogs, consistently gained weight at a greater rate over controls where methylsulfonylmethane was included in their water and/or food. This was observed at both low and high dosage levels, viz., about 60 and about 500 mg/day/kg body wt. A possible explanation for this is that any minor allergic response to the diet was neutralized by the ! methylsulfonylmethane. Additionally, the fur quality improved and somewhat faster nail growth was noted.

Weight increases were not seen with adult animals during comparable feeding experiments.
Example 19 - Parasite Infection (Enterobius) Laboratory mice determined by fecal cast examina-tion to have pin worms were given commercial feed anddrinking water, ad lib, both of which contained 2% by wt.
methylsulfonylmethane. Examination 17 days after test initiation indicated the fecal cast were free of worms and eggs. The blood level of methylsulfonylmethane in one animal examined exceeded 30 ppm.
Methylsulfonylmethane's ability in returning paEa-site susceptible tissue to noFmalcy where host injury is minimal or nil, suggests that methylsulfonylmethane in the diet aids in overcoming varied microbial in~ections, by stengthening body resistance theEeto rather than by direct attack on the organism.
Methylsulfonylmethane antagonizes anticholines-teEaseS in vivo, and possesses weak in VitEa antibacterial action~ for example, against Es~heriehia colir ~euconosto~
2~ citrovoEum, Salmonello typh~muriwm, Sta~hlococ~us aureus - and Stre@tococcus thermophi~us. It is a potent antifungal agent, demonstrating good antiparasitiQ a~tiv~ty at 500 p~m against Aspergillus nigeE, ~hytophthora ~innamomi and Sclerotium rolfsii. While not as potent or toxi~ to microbial populations as specific drug agents, by reason of its extremely low host systemic toxicity, methylsul-fonylmethane contrasts sharply with present antiinfective therapeutants and methodology. It is doubtful if chemical resistance will develop with infective agents controlled by high, but safe, systemic levels of methylsulfonyl-methane.
One can safely administer 1 - 2 grams/kg body wt.
of methylsulfonylmethane on a daily basis (equal to 1000-2000 ppm w/w basis). One therefore builds a safely tolerated blood level of about 4000 ppm, which level is ~2S~

highly toxic to many infective organism yet is harmless to tho host. Methylsulfonylmethane provides a unique new therapeutic approach, used alone or with concurrent, conventional therapy.
An evaluation of methylsulfonylmethane as concur-rent therapy with conventional anti-malaria drugs is indicated. Around one million humans die annually from this parasitic infection. Testing to date indicates that methylsulfonylmethane is a useful adjunct with the thera-peutic modalities used to combat adverse health problems by increasing a subject's baseline resistance to adversity and moderating untoward effects associated with arugs, vaccines and physical assaults against illnesses as by radiation or hyperthermia.
Example 20 - Vascular Complications Associated With Diabetes A~ subject (F.B., M 58), diagnosed to have diabetes mellitus 2~ years eaElier was seen with a serious vasculaE
~4 complication. ArteEiosclerosis has decEeased the a~terial 2~ blooa supply to the lower limbs, resulting in chronically cola feet and intermittent claudication. In addition, the subject had sufered a bruise to the foot which was not healing. This subject received 500 mg of methylsulfonyl-methane with 250 mg of ascorbic acid twice daily over a 2g period of 21 days. The first observed improvement was the healing rate of the bruise. By the end of the third week, the cold foot problem was partially relieved and the ; subject was able to double his walking distance without undo tiring. Post treatment laboratory workup suggested a possibility that his insulin requirement could be reduced.
Example 21 - Acute Pain Methylsulfonylmethane administered orally has proven useful in relieving acute pain in the mid-back region of an adult male caused by calculi obstructed ureter (single 1.5 gm dose dissolved in warm water) and pain spasms in the lower abdomen region of an adult female resulting from an accidental blow to the abdomen (two l gm doses in warm water at 4-hour intervals).
Example 22 - Low Platelet Count Methylsulfonylmethane administered orally raised the platelet count of an adult female with lupus erythematosus from 84,000 (after prednisone therapy) to 200,000 over a 2-year period (1.5 gm/day in 3 doses).
Example 23 - Sun and Wind surn Persons ingesting from 0.5-2 gm/day of methylsul-fonylmethane suffered only mildly from about 4 hours of exposure to summer sun and wind, whereas their companions who had not ingested methylsulfonylmethane were severely sun- and wind-burned.
Example 24 - Pleuritis Bilateral fibrinous pleuritis developed in a breeding mare with a respiratory infection, which did not respond to six weeks of conventional antibiotic and anti-inflammatory therapy, responded favorably (normal breathing, negative ausculation of the chest) after five days of methylsulfonylmethane (2 x 12 gm/day in diet).
Example 25 - Post-Athletic Activity Fatigue The physical fatigue syndrome following intense athletic activity in competitive sports which usually per~ist~ for 8 - 10 days in athletes was done in 2-3 days in individuals who had ingested methylsulfonylmethane (from 1-2 gm/day in split dosages) for the preceding six months.
Example 26 - Leg Cramps Administer methylsulfonylmethane to a geriatric patient (over 65 years) suffering from chronic night leg cramps at the rate of 10 mg/kg/day, either in tablet or capsule form, as described in U.S. Patent 4,568,547 or U.S. Patent 4,559,329, or in admixture with one or more foodstuffs ingested daily by the patient, e.g., milk, coffee, tea, cold desserts, etc. Within about iBlV~

2 days, the leg cramps will diminish in frequency or disappear.
Example 27 - Leg Cramps Before a marathon race, administer methylsulfonyl-methane to the runner for at least 7 days at the rate of 15 mg/kg/day. The likelihood of the runner experiencing severe leg cramp during or after the race will be significantly reduced.
Ex~mple 28 - Parasite Infection Control .

Methylsulfonylmethane has highly variable toxici-ties for various nematodes. Based on this discovery, tests were conducted on several parasi~es adverse to the health of vertebrates.
(a) Trichomonas vaqinalis lS Strain ATCC No. 30001 was cultured in vitro employing diamonds tym medium. Methylsulfonylmethane wa~
added theEeto at levels vaEyin~i fEoml ~.5', to~ 1~92. ~ m~ml.
At concentrations o S.S to 1~.9 mg~l, the m~hyl~ul-i fonylmethane had no eect on this pE~tO~Oa~. ~oweveE, at 21.9 mg/ml it was inhibitory and all higher concentrations were lethal to this paEasite. Based on this assay, methylsulfonylmethane is about half as active as metronidazole HCL.
Methylsulonylmethane was evaluated in vivo in conjunction with metronidazole HCL, given to two female subjects at a treatment level of 250 mg, taken every eight hours for ten days. Both had prior courses of therapy for this disorder without adequate response. Methylsulfonyl-methane was administered as 500 mg capsules with each Flagyl dose during the treatment period. During this course of treatment, neither patient experienced stomach upset and nausea, although this was a side effect experienced by one subject during the ~irst course of metronidazole HCL treatment alone.

`` -`` 1268123 The concurrent treatment of methylsulfonylmethane and Flagyl was successful in both cases, as confirmed by wet film examination. One subject was later reinfected by her sexual partner but the reinfection was cleared employing a daily douch of 5~ aqueous methylsulfonyl-methane for one week. The subject's partner was success-fully treated with 500 mg of methylsulfonylmethane given twice daily for two weeks.
(b) Giardia lamblia This mîcroorganism is associated with ~travelers diarrhea~, particularly where persistent and ~efractory to antimicrobial therapy. Like many inte~stinal parasites, there is vaEiable resistance to the organism by man, perhaps associated with receptor site availability and lS hence an immunological problem.
With this parasite, in vitro concentrations o~
methylsulfonylmethane o~ l mg/ml and lower demonstrated no significant inhibition of Giardia. However, at 20 mgiml concentration, it was stongly inhibitory ana concentra-tions above 40 mg~ml promptly ~illed the organism.
One subject with confirme~ Giardia, apparently " contacte~ ~rom contaminated wateE in a primitive area, was given 5~0~m~ o~ methylsulfonylmethane orally three times~24 hours X 14 days. By the eighth day he was asymptomati¢. Two stool specimens collected one wee~
apart were free of the organism.
(c) Enterobius ~, Laboratory mice determined by fecal cast examina-tion to have pin worms were given 2 % by wt. of methyl-sulfonylmethane in both their commercial feed and drinking water, ad lib. Fecal examination seventeen days after test initiation indicated the feces were free of worms and eggs.
Example 29 - Treatment of Lung Dysfunction Seven human subjects with respirator~ deficiency
12~3 were given methylsulfonylmethane by the oral route in amounts ranging from 250-1,500 mg/day, in single or ~- divided units. Five presented emphysema believed asso-ciated with cigarette smoking. Two presented tumor involvement of the lung with additional function impairment due to pleural fluid accumulation.
Two of five subjects with emphysema had prior cardiorespiratory function tests and follow-up evluations at six and eight weeks after starting a course of 500 mg/day orally of methylsulfonylmethane. Though both demonstrated several abnormal values prior to the test period, in particular lowered arterial~oxygen tension, both had values in the normal range while ingesting methylsulfonylmethane.
A more striking improvement was seen in physical achievement values determined with all subjects. Prior to and during the test period, at approximately two-week intervals, all presenting emphysema were re~uired to walk a measured distance compatible with their physical resources. Within 2-4 weeks of beginning the ingestion of methylsulfonylmethane, alone or with 1000 mg of ascorbic acid/day, all emphysema suferers had at least doubled their "comfortable" walking distance. Both subjects seen with lung tumors were evaluated by attending physicians and nurses as well as family as being more alert, comfortable, and with a better outlook and attitude than before the test period. The lung cavity fluid problem of each subject disappeared during the first months of the test period. Both were on radiation/chemotherapy prior to including methylsulfonylmethane in their diet, but without apparent benefit.
Example 30 - Canine Arthritis and Other Sources of Pain Methylsulfonylmethane was evaluated as an additive to the diet of older dogs of various breeds, all suffering from some form of arthritis and in some cases demonstrat-ing other disorders. In each case the methylsulfonyl-methane was admixed with the animal's food just prior to feeding.
(a) Dog A, a spayed, 15-year old German Shepherd, weighing 36 kg, demonstrated ataxia, virtual immobility with pain and joint stiffness. The animal was not responsive to cortisone or phenylbutazone. It was given 0.5 g/day of methylsulfonylmethane b.i.d. for 7 days without apparent benefit. Dosage was raised to 1.5 g/day b.i.d. and within 10 days the dog became freely mobile without evident discomfort nor demonst~rated ataxia.
(b) Dog B, a male, black Labrador, weighing 27 kg, demonstrated severe musculoskeletal comprise of the hind quarters with urinary incontinence. This animal, although owned by a veterinarian, had not responded to a variety of therapeutic regimens over the previous 12 months.
Methylsulfonylmethane was given to this dog in it's food ~!~ at a level of 1.5 qrams b.i.d. X 1 month. This dog derived no apparent benefit from methylsulfonylmethane, apparently due to the terminal nature.of its illness.
(c) Dog C, a spayed, 14-year old German Shepherd, demonstrated severe arthritis of the back and legs. It was mobile but walked with obvious difficulty and discom-fort. The animals was refractory to both cortisone andphenylbutazone. Methylsulfonylmethane was provided in the diet at a level of 0.5 grams b.i.d. There was gradual improvement in mobility over the first month. During the third month following methylsulfonylmethane supplementa-tion of the diet, the dog demonstrated neither musculo-skelatal restriction nor discomfort.
(d) Dog D, a female, mixed-breed Terrier, weighing 20 kg, demonstrated severe restriction in mobility and obvious discomfort with movement. The animal had not responded to either cortisone nor phenylbutazone and it's ~2~ 3 .. .. ~

condition was deteriorating rapidly. Methylsulfonyl-methane was included in its diet at 1 gm/day b.i.d. After one week, the dog appeared to be pain-free. This dog has received methylsulfonylmethane in its diet for over six months and remains apparently healthy and frisky, requiring no medication.
Example 31 - Pain in Humans The following patients suffering from intractible pain were given methylsulfonylmethane orally in the amounts and for the period of time set forth in the table ;ij; below:
Methylsulfonyl-methane Patient Aqe Sex Diagnosis Administration Results 1 P.A. 61 F Deg. Arth. 1 g 4X/day pain relief X 19 months B.A. 63 F Deg. Arth. 0.25 g qid pain relief C.A. 62 M Bursitis 0.25 g bid 50~ pain Chronic X 3 months relief 20 M.A. 55 F Rh. Arth. 0.25 g bid pain relief X 9 months !1l'. A.B. 69 F Deg. Arth. 0.5 bid pain relief X 18 months N.B. 62 M Tendonitis 0.25 g qid reduced pain 25 D.B. 35 M Low back 0.5 g qid pain relief pain X 9 months I.B. 62 F Multiple 0.5 bid muscle pain Sclerosis X 18 months reduction Deg. = Degenerative Rh. = Rheumatoid Arth.= Arthritis Example 32 - Acute Pain in Humans Methylsulfonylmethane was compared with codeine for the control of pain in subject J.H., a male, age 47, who awakened in the early morning with excruciating pain in the mid-back region, so intense it was difficult to pin-point a specific region.

~2t;~31X~

Subject had a past history of urinary calculi. Aspirin was ineffective but codeine provided acceptable relief during and after X-ray. Analgesic requirements were l/2 grain codeine with aspirin every two hours. During day two, subject complained of mental confusion and codeine was withdrawn. The intense pain returned. The subject was given 1.5 g of methylsulfonylmethane dissolved in l/2 glass of warm water. At 0.5 hours after taking the methylsulfonylmethane, the pain had essentially disappeared. Methylsulfonylmethane (1.5 g/day) was continued until the afternoon of the third day, when X-ray confirmed that the calculi yet obstruc,ted the ureter.
Subject was switched again to codeine with aspirin (l/2 grain X 2 hours). He reported less pain relief than was provided by methylsulfonylmethane. Methylsulfonylmethane was again administered (1.5 g X 4 hours). On day 5 the calculi passed. Recovery was uneventful, requiring neither codeine, methylsulfonylmethane, nor a urinary tract antimicrobial.
Example 33 - Acute Pain in Humans Codeine and methylsulfonylmethane were compare~
for the relief of pain in subject M.R., a female, age 26, who had sharp pain spasms in the lower abdominal region.
Subject's appendix had been removed. Pain began after suffering an accidental traumatic blow to the abdomen during a volley ball game. Pyelogram examination indicated no obstruction. The pain pattern suggested ureter spasm. Codeine (2) plus l/4 grain with aspirin every 4 hours, provided some relief. The codeine/aspirin was discontinued and l g methylsulfonylmethane in warm water was given. A half-hour later all discomfort ceased.
A second gram of methylsulfonylmethane in water was given 4 hours later, a~ter which the subject continued pain free.

3 l Example 34 - Intravenous Administration For patients suffering from a serious chronic disease, e.g., an acute stage of rheumatoid arthritis or other acute inflammatory conditions or a patient in extreme pain, administer 1 gm/kg of methylsulfonylmethane i.v. as a 14 % by wt. solution in sterile 5% dextrose solution, at the rate of 1 gm/kg/hr. Within 2 - 4 hours, significant subjective relief from the symptoms of the disease or condition is experienced by the patient, with the relief lasting for from 7 to 21 days.
Such massive i.v. administrations can be repeated as frequently as every 24 hours. Rates of dimethylsulfone administration as high as 2 gm/kg/hr are possible but may produce transient light-headedness in the patient.
_xample 35 - Myositis Ossificans Generalis An eight year old girl, A.Z., has demonstrated serious, irreversible myositis ossificans generalis. Her family belongs to a group of families each with a family member suffering from the disease. She has been on one ~0 teaspoon of methylsulfonylmethane orally, in split daily doses f OF nea}ly two years. The disease process has stopped, she is out of her wheelchair and is impEOVing.
No other child in the group is on methylsulfonylmethane and all are deteriorating physically. The disease cause is unknown but probably is a genetic/autoimmune type of disorder.
Example 36 - Resistance to DMBA-Induced Mammary Carcinoma Forty-five female rats were stabilized to the laboratory and then divided into 3 groups of 15 each.
Group 1 was designated control, Groups 2 and 3 were treated by topical application to the hair-free abdomen with a solution of the carcinogen dimethyl-ben2anthracene (DMBA). All three groups were each fed a standard labo-ratory diet with water, ad lib. Group 3 also received in their standard diet 2% by wt. of methylsulfonylmethane.

At 5 months post treatment with DNBA, both the control normal and Group 3 animals were free of mammary carcinoma. The Group 2 animals demonstrated chemically induced mammary cancers and were sacrificed, Example 37 - Arresting the Development of Spontaneous Nouse Lymphomas Laboratory mice genetically predisposed to lymphoma development were selected for this test. Humoral immunity participation was measured as was the effect of methylsulfonylmethane on an animal's life span. One set of 12 mice were maintained as controls. The treated (LT) group received identical treatment except for their water given ad lib, which contained 3% by wt. of methylsulfonylmethane in solution.
By month 4 of this test, all controls were dead, due to lymphoma development. No T group mice had died by month 5. These normal balb/c strain mice of group T were tested for t-lymphocyte dependent (t-d) and t-lymphocyte independent (t-i) immune responses. Nice given methyl-sulfonylmethane demonstrated significantly enhancement of primary IgM and secondary IgG responses to sheep erythrocytes (SRBC), with significant suppression of the tnp-ficoll response. Based on these preliminary results, at high enough daily rates of ingestion, methylsulfonylmethane stimulates humoral immunity thereby providing protection to otherwise lethal spontaneous mouse lymphomas.
It can be seen from the foregoing and from the disclosure of U.S. Patent 4,568,547 dealing with the ameliorating of the symptoms of stress and of allergies, that methylsulfonylmethane is useful in maintaining or improving the health of a variety of animals in a variety of ways.
The preceding examples can be repeated with similar success by substituting the generically or speci-~;81i~3 fically described reactants and/or operating conditions of this invention for those used in the preeeding examples.
From the foregoing deseription, one skilled in the art can easily ascertain the essential charaeteristics S of this invention, and without departing from the spirit and seope thereof, ean make various changes and modifieations of the invention to adapt it to various usages and conditions.

,;~
' 20

Claims (16)

WHAT IS CLAIMED IS:
1. A method of providing a source of metabolizable sulfur to an animal whose diet comprises sufficient processed food to render the animal's diet deficient in metabolizable sulfur, which comprises incorporating into one or more of the foodstuffs ingested daily by the animal an amount of methylsulfonylmethane equivalent to at least 0.01 mg/kg thereafter of body weight per day.
2. A method of processing a foodstuff which involves the step of reducing the moisture content thereof by heating or drying the effect of which is to reduce any naturally occurring methylsulfonylmethane present therein to a level of less than about 0.1 ppm, which comprises the step of admixing with the foodstuff after said heating or drying step an amount of methylsulfonylmethane effective to raise the concentration thereof in the foodstuff to at least about one ppm.
3. A method according to Claim 2, wherein the foodstuff is pasteurized milk or milk product.
4. A method according to Claim 2, wherein the foodstuff is a dry breakfast cereal.
5. A method according to Claim 2, wherein the foodstuff is cooked in an open vessel at or above 100°C.
6. A method according to Claim 2, wherein the foodstuff is one which is conventionally ingested by a herbivore.
7. A method according to Claim 2, wherein the foodstuff is one which is conventionally ingested by a fowl.
8. A method according to Claim 2, wherein the foodstuff is one which is conventionally ingested by a human being.
9. A cooked and/or dried processed foodstuff which after processing contains less than 0.1 ppm of naturally occurring methylsulfonylmethane, comprising, in physical admixture therewith, from about 15 x 10-4 % to 3% of exogenous methylsulfonylmethane.
10. A dry processed foodstuff according to Claim 9.
11. A processed foodstuff according to Claim 9, said foodstuff being one which is conventionally ingested by a human being.
12. A pasteurized milk or milk product according to Claim 9.
13. A processed foodstuff according to Claim 9, adapted for feeding a domestic animal.
14. A dry processed foodstuff according to Claim 11, containing therein methylsulfonylmethane in discrete form, in addition to any naturally occurring methylsulfonylmethane present in other ingredients of the ration, in an amount effective to provide at least 0.1 mg/day/kg of body weight of an animal ingesting the ration in normal daily amounts.
15. A processed foodstuff acording to Claim 14, as an animal feedstuff ration which is conventionally fed to a herbivore.
16. A processed foodstuff according to Claim 18, as an animal feed conventionally fed to an animal selected from the group consisting of cattle, pigs, horses, sheep, goats, fish and fowl, and consisting essentially of one or more of the ingredients corn, hay, alfalfa, corn silage, soybean meal, meat meal, fish meal, dehydrated alfalfa meal, minerals and vitamins normally eaten by such an animal.
CA507074A 1985-04-29 1986-04-18 Dietary products and uses comprising methylsulfonylmethane Expired CA1268123C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA507074A CA1268123C (en) 1985-04-29 1986-04-18 Dietary products and uses comprising methylsulfonylmethane

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/727,989 US4616039A (en) 1979-08-30 1985-04-29 Methylsulfonylmethane in dietary products
US727,989 1985-04-29
CA507074A CA1268123C (en) 1985-04-29 1986-04-18 Dietary products and uses comprising methylsulfonylmethane

Publications (2)

Publication Number Publication Date
CA1268123A true CA1268123A (en) 1990-04-24
CA1268123C CA1268123C (en) 1990-04-24

Family

ID=24924965

Family Applications (1)

Application Number Title Priority Date Filing Date
CA507074A Expired CA1268123C (en) 1985-04-29 1986-04-18 Dietary products and uses comprising methylsulfonylmethane

Country Status (10)

Country Link
US (1) US4616039A (en)
EP (1) EP0200526B1 (en)
JP (1) JPH082268B2 (en)
KR (1) KR900002027B1 (en)
AT (1) ATE86826T1 (en)
AU (1) AU592333B2 (en)
CA (1) CA1268123C (en)
DE (1) DE3687996T2 (en)
DK (1) DK195586A (en)
NO (1) NO861673L (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071878A (en) * 1979-08-30 1991-12-10 Herschler R J Use of methylsulfonylmethane to enhance diet of an animal
US4863748A (en) * 1979-08-30 1989-09-05 Herschler R J Dietary products and uses comprising methylsulfonylmethane
US4504122A (en) * 1983-04-21 1985-03-12 General Dynamics Corporation/Convair Div. System and method for time sharing laser system which also generates a local oscillator signal
JPH0749124B2 (en) * 1986-03-20 1995-05-31 株式会社日立製作所 Roll shift rolling mill
US4877773A (en) * 1987-04-29 1989-10-31 Turner Leola E B Pharmaceutical preparation
GB2213057A (en) * 1987-12-08 1989-08-09 I Pascuchi Josep Maria Vich Anti-viral agent
JPH0975010A (en) * 1995-09-18 1997-03-25 Araya:Kk Physiological activation agent for fish and feed additive for pisciculture
US6203820B1 (en) * 1998-05-28 2001-03-20 Brice E. Vickery Compositions and methods for enhancing protein anabolism and detoxification
US6663874B2 (en) 1998-11-02 2003-12-16 Victor Stevens Composition to alleviate pain and topical method of applying same
CA2386423C (en) * 1999-10-04 2009-07-21 John Carter Pharmaceutical compositions containing copper, salicylic acid and vitamines c
US20030235629A1 (en) * 1999-11-06 2003-12-25 Janmarie Hornack Dietary supplement containing alkaline electrolyte buffers
US6793942B2 (en) 2000-02-23 2004-09-21 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
US6759062B2 (en) 2000-02-23 2004-07-06 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
US6787164B2 (en) 2000-02-23 2004-09-07 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
US6841544B2 (en) * 2000-02-23 2005-01-11 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
US6403116B1 (en) 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
US6902739B2 (en) * 2001-07-23 2005-06-07 Nutracea Methods for treating joint inflammation, pain, and loss of mobility
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
US20040029774A1 (en) * 2002-08-06 2004-02-12 Aly Gamay Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies
US6660308B1 (en) 2002-09-11 2003-12-09 Kenneth A. Martin Beverage and additive for the ill
US6900173B2 (en) * 2002-09-11 2005-05-31 Kenneth A. Martin Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery
US20040254095A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Supplement for treating musculoskeletal disorders
US20040253296A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Food bar for treating musculoskeletal disorders
US20040253227A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery
JP2005298412A (en) * 2004-04-13 2005-10-27 Minato Pharmaceutical Co Ltd Coated particle
JPWO2005112667A1 (en) * 2004-05-20 2008-03-27 隆史 大森 healthy food
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
US20060147423A1 (en) * 2004-12-07 2006-07-06 Jean-Yves Legendre Transungual device
KR100707848B1 (en) * 2005-04-26 2007-04-13 권석은 Nutrition Solution containing methyl sulfonyl methane, the method of manufacturing the same, the method of raising chicken by feeding the same, the chicken by the method, and egg containing methyl sulfonyl methane
US20070021505A1 (en) * 2005-07-15 2007-01-25 Chakshu Research, Inc Prevention and treatment of ophthalmic complications of diabetes
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
EP1937286B1 (en) 2005-09-12 2016-03-09 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (dmso)
JP5399072B2 (en) 2005-09-12 2014-01-29 アベラ ファーマスーティカルズ インコーポレイテッド System for removing dimethyl sulfoxide (DMSO) or related compounds or odors associated therewith
BRPI0921494A2 (en) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd method of planning a underground forming sampling operation, method of controlling a underground forming sampling operation, method of controlling a drilling operation for an underground formation, and method of sampling during the drilling operation.
WO2010141889A1 (en) * 2009-06-05 2010-12-09 Biogenic Innovations, Llc Use of methylsulfonylmethane as a taste masking agent
NZ600134A (en) * 2009-10-30 2014-08-29 Biogenic Innovations Llc Methylsulfonylmethane (msm) for treatment of drug resistant microorganisms
CA2779111C (en) 2009-10-30 2019-08-13 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis
AU2011313814B2 (en) * 2010-10-07 2015-12-24 Eaglepharma Pty Ltd Combination therapy for the treatment of depression and other non-infectious diseases
FI126459B (en) * 2011-02-03 2016-12-15 Stora Enso Oyj Process for the preparation of dimethyl sulfone
US11241464B2 (en) 2013-06-13 2022-02-08 Altera International, Ltd. Methods of improving reproductive and respiratory health
KR101868312B1 (en) * 2018-01-12 2018-06-15 이병관 Method for feeding methyl sulfonyl methane to laying hens
KR102278911B1 (en) * 2020-08-10 2021-07-19 주식회사 잇다 Pig feed method for each breeding stage
CN113598277A (en) * 2021-07-09 2021-11-05 广州清科生物技术有限公司 Enzymolysis pet dog and cat food and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4333922A (en) 1974-09-12 1982-06-08 Herschler R J Method for the treatment of water-living animals with health modifying agents
US4296104A (en) 1979-08-30 1981-10-20 Herschler R J Therapeutic dimethyl sulfoxide composition and methods of use
US4296130A (en) * 1979-08-30 1981-10-20 Herschler R J Methylsulfonylmethane and methods of use
US4514421A (en) * 1979-08-30 1985-04-30 Herschler R J Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it
US4477469A (en) * 1979-08-30 1984-10-16 Herschler R J Preparations containing methylsulfonylmethane and methods of use and purification

Also Published As

Publication number Publication date
EP0200526B1 (en) 1993-03-17
US4616039A (en) 1986-10-07
KR900002027B1 (en) 1990-03-31
DK195586A (en) 1986-10-30
EP0200526A2 (en) 1986-11-05
AU5609186A (en) 1986-11-06
EP0200526A3 (en) 1989-02-15
NO861673L (en) 1986-10-30
ATE86826T1 (en) 1993-04-15
DE3687996T2 (en) 1993-06-24
DE3687996D1 (en) 1993-04-22
KR880003618A (en) 1988-05-28
JPS6212A (en) 1987-01-06
DK195586D0 (en) 1986-04-29
JPH082268B2 (en) 1996-01-17
AU592333B2 (en) 1990-01-11
CA1268123C (en) 1990-04-24

Similar Documents

Publication Publication Date Title
CA1268123A (en) Dietary products and uses comprising methylsulfonylmethane
US5071878A (en) Use of methylsulfonylmethane to enhance diet of an animal
US4863748A (en) Dietary products and uses comprising methylsulfonylmethane
US4973605A (en) Use of methylsulfonylmethane to relieve pain and relieve pain and nocturnal cramps and to reduce stress-induced deaths in animals
US4914135A (en) Use of Methylsulfonylmethane to treat parasitic infections
US20030194423A1 (en) Composition for enhancing nutritional content of food
EP1913943B1 (en) Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria
US7824705B2 (en) Physiologically active agents containing vicinal dithioglycols and use thereof in various branches of economy
JP2003508069A (en) Pet food product and method of manufacturing it
JP2009197030A (en) Mucosal immunomodulator and its use
CA2631837A1 (en) Equine whole food supplements
US20150196048A1 (en) Bovine meat compositions having enhanced quality, nutritive and health values obtained from enrichment diets
McCollum et al. The" vitamine" hypothesis and deficiency diseases: a study of experimental scurvy
JP2006197911A (en) Health food using bee larva
US9474292B1 (en) Nutritional powder including brewer&#39;s yeast, aronia extract, and cranberry extract for animals
Page et al. Your Body is Your Best Doctor!: Formerly, Health Versus Disease
JP2010524441A (en) Novel use of hydroxytyrosol and olive extract / concentrate containing it
CN103975896B (en) Reduce the raising method of partly raising heavy metal antibiotic residue in traditional black Meat scattered
Abd-Allah et al. Influence of using flavomycin and propolis as feed additives on buffalo milk production, and growth performance and blood metabolites of suckling calves
CHIMBAKA et al. FORMANCE OF RABBITS (ORYCTOLAGUSCUNICULUS)
JPH11266795A (en) Nutritive assistance feed for pet
Ajimohun et al. Effects of varying levels of Moringa oleifera leaf meal on growth, haematology and blood serum components of weaner rabbits
Van Nuys Deficiency Diseases
JP2008546834A (en) Parenteral selenomethionine for the production of selenium rich foods
Southwood 22 Long-term Recovery and Prevention

Legal Events

Date Code Title Description
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121205